Development and Validation of Stability Indicating LC-PDA Method for Mycophenolate Mofetil in Presence of Mycophenolic Acid and Its Application for Degradation Kinetics and pH Profile Study
Factorial design tool applied for development of isocratic reversed-phase stability-indicating HPLC method for the analysis of mycophenolate mofetil (MMF) and its degradation products. MMF stress degradation products mycophenolate acid (MPA) and DP3 (USP impurity H) were isolated and used for quantitation. Separation achieved on a Symmetry C18 (250?mm × 4.6?mm, 5.0?μ) column using a methanol: acetate buffer (75?:?25?v/v), pH 6.0 (adjusted with acetic acid), at 0.5?mL flow rate, column maintained at 55°C, and data integrated at 251?nm. MMF is subjected to hydrolysis, oxidation, heat degradation, and so forth; under all these conditions degraded products are well separated. The method validation characteristics included accuracy, precision, linearity, range, specificity, and sensitivity. Robustness testing is conducted to evaluate the effect of minor changes to the chromatographic conditions and to establish appropriate system suitability parameters. The proposed method is used to investigate kinetics of acid, alkali hydrolysis and oxidation process. Major degradation products MPA and DP3 were isolated and quantitated. Characterization of MPA by NMR and LC-MS/MS and other degraded products by LC-MS/MS is attempted successfully. The method is used successfully for the quality assessment of three MMF drug commercial formations and its acid, alkali, and oxidative degradation kinetics study. 1. Introduction Mycophenolate mofetil (MMF) is chemically 2-(morpholin-4-yl) ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate. It is inhibitor of nucleic acid synthesis. It is the ester moiety of mycophenolic acid (MPA). It is a white or almost white crystalline powder and is used as immunosuppressive [1]. HPLC and HPTLC analytical methods for dissolution study of MMF in capsules, for its assay in bulk and dosage forms, [2–6] are reported. Bioanalytical and immunoassay methods are available for its determination individually or in presence of MPA [7–9] and one UV dissolution method is reported [10]. Its degradation products in aqueous solution are studied [11]. Stability-indicating HPLC and LC-MS/MS methods [12, 13] are reported where structural elucidation of degraded product and separation of the stress degraded product is lacking. MMF is included in BP, EP, and USP and assayed by potentiometry [14, 15]. Isocratic LC method was described in proposed USP monograph [16, 17] for MMF tablet and capsule assay using mobile phase acetonitrile?:?water containing 0.3% triethylamine (30?:?20?v/v), pH 5.3 (adjusted with
References
[1]
S. Budavari, The Merck Index, Merck & Co., Whitehouse Station, NJ, USA, 14th edition, 2001.
[2]
L. Yang and D. He, “HPLC determination of dissolution of mycophenolate mofetil capsules,” Yaowu Fenxi Zazhi, vol. 28, no. 7, pp. 1177–1179, 2008.
[3]
A. L. Rao, P. V. Srinivas, and J. V. L. N. S. Rao, “A new validated RP-HPLC method for the estimation of mycophenolate mofetil in pure and tablet dosage form,” Journal of Pharmaceutical Research and Health Care, vol. 2, no. 3, pp. 266–269, 2010.
[4]
P. Raja Abhilash, K. Vasanth Kumar, and V. Sateesh Kumar, “Development and validation of new RP-UPLC method for the quantitative analysis of mycophenolate in tablet dosage form,” The British Journal of Pharmaceutical Research, vol. 3, no. 3, pp. 363–373, 2013.
[5]
K. Rajendra Prasad and S. Kathirvel, “Development and validation of RP-HPLC method for estimation of mycophenolate mofetil in bulk and pharmaceutical dosage form,” Research Journal of Pharmaceutical Dosage Form and Technology, vol. 5, no. 1, pp. 43–46, 2013.
[6]
S. Kathirvel, P. K. Rajendra, and B. K. Madhu, “Development and validation of HPTLC method for the determination of mycophenolate mofetil in bulk and pharmaceutical formulation,” Pharmaceutical Methods, vol. 3, no. 2, pp. 90–93, 2012.
[7]
U. D. Renner, C. Thiede, M. Bornh?user, G. Ehninger, and H.-M. Thiede, “Determination of mycophenolic acid and mycophenolate mofetil by high-performance liquid chromatography using postcolumn derivatization,” Analytical Chemistry, vol. 73, no. 1, pp. 41–46, 2001.
[8]
I. Tsina, M. Kaloostian, R. Lee, T. Tarnowski, and B. Wong, “High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma,” Journal of Chromatography B: Biomedical Applications, vol. 681, no. 2, pp. 347–353, 1996.
[9]
J. L. Beal, C. E. Jones, P. J. Taylor, and S. E. Tett, “Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay,” Therapeutic Drug Monitoring, vol. 20, no. 6, pp. 685–690, 1998.
[10]
S. P. Verma, O. Alam, P. Mullick, and N. Siddiqui Validated, “Ultra Violet Spectroscopy method for the dissolution study of mycophenolate mofetil immediate release 500 mg tablets,” Nature Precedings, 2009.
[11]
E. Hooijmaaijer, M. Brandl, J. Nelson, and D. Lustig, “Degradation products of mycophenolate mofetil in aqueous solution,” Drug Development and Industrial Pharmacy, vol. 25, no. 3, pp. 361–365, 1999.
[12]
A. Proti?, L. ?ivanovíc, M. Ze?evi?, and B. Joci?, “Development of liquid chromatographic method for simultaneous determination of mycophenolate mofetil and its degradation product mycophenolic acid in dosage form,” Journal of Chromatographic Science, vol. 47, no. 2, pp. 149–155, 2009.
[13]
T. V. B. Reddy, N. S. Reddy, R. Golkonda, V. V. Sure, and R. Chintala, “Development of stability indicating liquid chromatography-mass tandem spectrometric method for the estimation of mycophenolate mofetil in bulk and pharmaceutical formulations,” Journal of Pharmacy Research, vol. 7, pp. 640–646, 2013.
[14]
British Pharmacopoeia, 6th edition, 2009.
[15]
European Pharmacopoeia, European Directorate for the Quality of Medicines and Health Care, Council of Europe, Strasbourg, France, 6th edition, 2008.